ライフサイエンスコーパス: hospitalisation

1 e as the difference observed after a week of hospitalisation.

2 ther as a result of illness and particularly hospitalisation.

3 at high risk of venous thromboembolism after hospitalisation.

4 ounting for up to 30% of adult heart failure hospitalisations.

5 order, were found for psychiatric inpatient hospitalisation (adjusted relative risk [aRR] = 2.0; 95%

6 ses in 2013, -78%, 95% CI -72 to -83) and in hospitalisation admissions (440 admissions in 2012 vs 14

7 is 13 billion euros, mainly accounted for by hospitalisation after fracture.

8 photericin B administration requires patient hospitalisation and careful laboratory monitoring to ide

9 P) levels have been shown to predict risk of hospitalisation and death from COPD.

10 lose temporal association with heart failure hospitalisation and heart failure mortality.

11 acute decompensated heart failure including hospitalisation and heart failure mortality.

12 Hospitalisation and mortality events were documented for

13 reducing the delay between symptom onset and hospitalisation and rapid national and international res

14 uce the number and associated costs of child hospitalisations and clinical visits for acute diarrhoea

15 Three had severe disease with multiple hospitalisations and complications but responded promptl

16 food borne pathogen responsible for numerous hospitalisations and deaths all over the world.

17 .9 mug/m(3) would prevent 7978 heart failure hospitalisations and save a third of a billion US dollar

18 s not associated with a reduction in overall hospitalisations and was associated with an increase in

19 utcomes were: total, elective, and emergency hospitalisations, and total and GP-referred specialist v

20 es complications from abortion procedures or hospitalisation are rare.

21 dpoint was the rate of heart-failure-related hospitalisations at 6 months.

22 tion could lead to a substantial increase in hospitalisation because of dengue.

23 f outpatient specialist visits and inpatient hospitalisations before and after the implementation of

24 ent, including all cardiovascular deaths and hospitalisations, between 1989 and 1995.

25 s 29%, p=0.017), reduced duration of initial hospitalisation, but higher risk of chronic myelogenous

26 er country experienced a change in trends in hospitalisations: change in slope for total, elective, a

27 had a 39% reduction in heart-failure-related hospitalisation compared with the control group (153 vs

28 Safe funeral practices and fast hospitalisation contributed to the containment of this E

29 riven revascularisation and ischaemia-driven hospitalisation did not differ significantly between gro

30 nor was there a difference in the number of hospitalisations due to relapsing IBD during follow-up.

31 roid dosing protocol to periods of prolonged hospitalisation during the first 3 postoperative months

32 ation between depression and non-psychiatric hospitalisation episodes has never been researched in gr

33 t use and non-elective CEA (performed during hospitalisation for a symptomatic ipsilateral stroke, tr

34 h people with mental health problems) during hospitalisation for acute illness were analysed using a

35 Hospitalisation for adversity-related injury (violent, d

36 between intelligence and subsequent risk of hospitalisation for bipolar disorder in a prospective co

37 ite of time to death from any cause or first hospitalisation for cardiovascular reasons.

38 pation fails, the patient may need emergency hospitalisation for disimpaction.

39 tly lower in France, the UK and Germany, and hospitalisation for headache was significantly more freq

40 t ventricular (LV) systolic dysfunction, and hospitalisation for heart failure or intravenous drug th

41 widen understanding for the global burden of hospitalisation for hypoglycaemia.

42 bral malaria began to change 10 years before hospitalisation for malaria started to fall.

43 showing a significant and large reduction in hospitalisation for patients with NYHA class III heart f

44 er, nonliver, and all-cause mortality; first hospitalisation for severe liver morbidity (SLM); cardio

45 scular endpoint (which additionally included hospitalisation for unstable angina requiring unplanned

46 t non-fatal myocardial infarction or stroke, hospitalisation for unstable angina, arterial revascular

47 s-old young woman with a history of multiple hospitalisations for foci of vascular anomalies appearin

48 e show a significant increase (1.2%-267%) in hospitalisations for respiratory diseases in children un

49 d neurological deficits following treatment, hospitalisation >5 days, overall morbidity and mortality

50 d by 14% considering the general increase in hospitalisation; however, accounting for diabetes preval

51 iratory virus infection is a common cause of hospitalisation in adults.

52 mic monitoring systems might reduce rates of hospitalisation in patients with heart failure.

53 Aerosol was the primary driver of hospitalisations in drought affected municipalities duri

54 g that reduced funeral attendance and faster hospitalisation independently influenced local transmiss

55 ich safe burials are increased and effective hospitalisation instituted under two scenarios: (i) one

56 d old age is associated with non-psychiatric hospitalisation, longer length of stay and higher mortal

57 Serious adverse reactions necessitating hospitalisation occurred in 33 infants (16 on hormonal t

58 uneral contacts: severe symptoms, death, non-hospitalisation, older age, and travelling prior to symp

59 The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard r

60 entration were associated with heart failure hospitalisation or death (PM2.5 2.12% per 10 mug/m(3), 9

61 Heart failure hospitalisation or death was associated with increases i

62 For the incidence (hospitalisation or death) rates of specific diseases, RR

63 ed to a different treatment model because of hospitalisation or travel (58 patients), leaving 4,173 T

64 um [PM10]) air pollutants, and heart failure hospitalisations or heart failure mortality.

65 chiatric disorders and psychiatric inpatient hospitalisation, premature mortality (before age 41 y),

66 The annual hospitalisation rate varies from a low of about 3 per 10

67 evidence for decreased acute chest syndrome, hospitalisation rates, and transfusion.

68 There was evidence that hospitalisation reduced but did not eliminate onward exp

69 sequelae; and (iii) compare sequelae risk by hospitalisation status and pathogen.

70 uropean countries, but less likely to report hospitalisation than in Canada and Australia.

71 The combination of mask use with reduced hospitalisation time and a shift to outpatient therapy c

72 incidence rate ratio for repeat ED visits or hospitalisations was 0.89 (95% CI, 0.86 to 0.93) for sei

73 ts diagnosed prior to or up to 30 days after hospitalisation were defined as prevalent diabetes and w

74 No serious adverse events requiring hospitalisation were reported after immunisation.

75 in slope for total, elective, and emergency hospitalisations were -0.2% (95% CI -0.6%-0.2%; p = 0.25

76 In 6 months, 83 heart-failure-related hospitalisations were reported in the treatment group (n

77 ence of peripheral artery disease (including hospitalisation with a diagnosis of peripheral artery di

78 Risk of hospitalisation with any form of bipolar disorder fell i

79 ed, was associated with an increased risk of hospitalisation with asthma but no difference in risk of

80 Risk of hospitalisation with asthma was greater following both u

81 tcomes assessed included obesity at age 5 y, hospitalisation with asthma, learning disability, cerebr

82 Hospitalisations with a discharge diagnosis of an acute

83 ate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients wi

84 driven revascularisation or ischaemia-driven hospitalisation without revascularisation.